#TBT: Read the trending study about patients with HPV-negative #oropharyngeal cancers treated with #Nimotuzumab #cisplatin & #radiation therapies ➡️ https://t.co/btJ6NjQKHr #oralcancer https://t.co/UUyyjN4U1k
RT @DrVijayPatil11: Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer | Oncotarget https://t.…
RT @DrVijayPatil11: Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer | Oncotarget https://t.…
RT @DrVijayPatil11: Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer | Oncotarget https://t.…
Impressive , addition of nimotuzumab to weekly cisplatin-radiation improves outcomes and OS in HPV negative oropharyngeal cancers.@joydeepGonco @IJMPOofficial @CRSTonline @SirohiBhawna @DrVikasAsati @khizmatghar @todrashish
RT @DrVijayPatil11: Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer | Oncotarget https://t.…
RT @DrVijayPatil11: Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer | Oncotarget https://t.…
RT @DrVijayPatil11: Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer | Oncotarget https://t.…
RT @DrVijayPatil11: Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer | Oncotarget https://t.…
RT @DrVijayPatil11: Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer | Oncotarget https://t.…
RT @IJMPOofficial: Astonishing and thought provoking data this from @ACTREC_TMC Congratulations to @VanitaNoronha @DrVijayPatil11 et al aga…
RT @DrVijayPatil11: Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer | Oncotarget https://t.…
RT @DrVijayPatil11: Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer | Oncotarget https://t.…
Astonishing and thought provoking data this from @ACTREC_TMC Congratulations to @VanitaNoronha @DrVijayPatil11 et al again Nimo+ CDDP synergy? The 2- year PFS was 31.5% (95%CI 21.5–42) in CRT arm versus 57.2% (95%CI 45.8–67.1) in NCRT arm (HR -0.54; 95%CI
RT @DrVijayPatil11: Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer | Oncotarget https://t.…
Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer | Oncotarget https://t.co/jrDsmSx0tK @VanitaNoronha @CRSTonline @IJMPOofficial @mahimkar_manoj @SachinD78722095
Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer | Oncotarget https://t.co/ukjwjwbX3f
RT @VanitaNoronha: In HPV neg oropharyngeal CA, the addition of Nimotuzumab to CRT improved LCR, PFS and OS #HNCSM #headandneckcancer @IJMP…
RT @VanitaNoronha: In HPV neg oropharyngeal CA, the addition of Nimotuzumab to CRT improved LCR, PFS and OS #HNCSM #headandneckcancer @IJMP…
RT @VanitaNoronha: In HPV neg oropharyngeal CA, the addition of Nimotuzumab to CRT improved LCR, PFS and OS #HNCSM #headandneckcancer @IJMP…
RT @VanitaNoronha: In HPV neg oropharyngeal CA, the addition of Nimotuzumab to CRT improved LCR, PFS and OS #HNCSM #headandneckcancer @IJMP…
RT @VanitaNoronha: In HPV neg oropharyngeal CA, the addition of Nimotuzumab to CRT improved LCR, PFS and OS #HNCSM #headandneckcancer @IJMP…
RT @VanitaNoronha: In HPV neg oropharyngeal CA, the addition of Nimotuzumab to CRT improved LCR, PFS and OS #HNCSM #headandneckcancer @IJMP…
RT @VanitaNoronha: In HPV neg oropharyngeal CA, the addition of Nimotuzumab to CRT improved LCR, PFS and OS #HNCSM #headandneckcancer @IJMP…
RT @VanitaNoronha: In HPV neg oropharyngeal CA, the addition of Nimotuzumab to CRT improved LCR, PFS and OS #HNCSM #headandneckcancer @IJMP…
The addition of nimotuzumab to CRT lead to an improvement in 2-year OS from 39.0% to 57.6 % (p = 0.018). Kudos to @VanitaNoronha et al for this potentially practice changing paper . Our heartiest congratulations !! @PSKulkarni @venkymd @VirajLavingia @S
In HPV neg oropharyngeal CA, the addition of Nimotuzumab to CRT improved LCR, PFS and OS #HNCSM #headandneckcancer @IJMPOofficial https://t.co/5aB6T7Vjq1